ArticleCaspian journal of internal medicine2016
Benefits from the correction of vitamin D deficiency in patients with pulmonary hypertension.
Article in Caspian journal of internal medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 29 citations in OpenAlex.
- Vitamin D receptor and its antiproliferative effect in human pulmonary arterial hypertension.Scientific reports · 2024Article
- Impact of malnutrition on prognosis in patients with pulmonary arterial hypertension.Pulmonary circulation · 2023Article
- A review of cardio-pulmonary microvascular dysfunction in pulmonary hypertension.American heart journal plus : cardiology research and practice · 2023Article
- Association of nutritional status and mortality risk in patients with primary pulmonary hypertension.Pulmonary circulation · 2022Article
- Why Pulmonary Vasodilation May Be Part of a Key Strategy to Improve Survival in COVID-19.Cureus · 2021Article
- Prevalence of Micronutrient Deficiencies and Relationship with Clinical and Patient-Related Outcomes in Pulmonary Hypertension Types I and IV.Nutrients · 2021Observational
- Restoration of Vitamin D Levels Improves Endothelial Function and Increases TASK-Like KBiomolecules · 2021Article
- Novel Experimental Therapies for Treatment of Pulmonary Arterial Hypertension.Journal of experimental pharmacology · 2021Review
- Dietary supplementation of 25-hydroxycholecalciferol improves cardiac function and livability in broiler breeder hens-amelioration of blood pressure and vascular remodeling.Poultry science · 2020Article
- Geriatric Nutritional Risk Index Is Associated With Prognosis in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension.Circulation reports · 2020Article
- Total, Bioavailable, and Free Vitamin D Levels and Their Prognostic Value in Pulmonary Arterial Hypertension.Journal of clinical medicine · 2020Article
- Impact of Nutrition on Pulmonary Arterial Hypertension.Nutrients · 2020Review
- Vitamin D deficiency among patients with pulmonary hypertension.BMC pulmonary medicine · 2019Article
- Malnutrition in pulmonary arterial hypertension: a possible role for dietary intervention.Current opinion in pulmonary medicine · 2019Review
- Current status of pulmonary arterial hypertension in Korea.The Korean journal of internal medicine · 2019Review
- Increasing quality of life in pulmonary arterial hypertension: is there a role for nutrition?Heart failure reviews · 2018Review
- Pulmonary arterial hypertension: tailoring treatment to risk in the current era.European respiratory review : an official journal of the European Respiratory Society · 2017Review
- Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension.Pulmonary circulationArticle
- Cardiac arrest and pulmonary hypertension in scurvy: a case report.Pulmonary circulationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D (Vit D) is linked to various conditions including musculoskeletal, metabolic and cardiopulmonary diseases. However, it is not clear whether correction of vit D deficiency exerts any beneficial effect in patients with pulmonary hypertension.
methodsThis study was a prospective uncontrolled longitudinal study. Patients with pulmonary hypertension and vit D deficiency were enrolled into this study. All patients in addition to standard treatment for pulmonary hypertension received cholecalciferol at a dose of 50,000 IU weekly plus calcicare (at a dose of 200 mg magnesium + 8 mg zinc + 400 IU vit D) daily for 3 months. Serum level of 25-hydroxy vit D, serum level of pro-brain natriuretic peptide, six minute walk test (6MWT), peak and mean pulmonary artery pressure, right ventricular size and function, ejection fraction (EF) and New York Heart Association (NYHA) functional class were measured at baseline and after 3 months of treatment.
resultsTwenty-two patients with pulmonary hypertension and vit D deficiency were enrolled into the study. At endpoint, the serum vit D level increased significantly to 54.8 ng/ml, the mean of baseline distance of 6MWT increased significantly to 81.6 m and the RV size significantly improved. The mean pulmonary artery pressure also improved after the intervention, but their changes did not reach to statistically significant levels.
conclusionVit D replacement therapy in patients with pulmonary arterial hypertension and vit D deficiency results in significant improvement of right ventricular size and 6 MWT. Moreover, mean pulmonary artery pressure improves nonsignificantly. This issue requires further studies with long-term follow-up period.
Indexed as
Identifiers
27999642PMC5153516W2562626055What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.